StockFin.ai
/
Sign inTry Free

Tools

Search Companies
News & Filings
Insights & Articles
FeaturesComing Soon
Pricing

Epigral Limited (EPIGRAL) — Financial Results | 27 July 2026 (2 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings
1Financial Results🔴 High Importance Neutral📄 PDF
📢 Key Event
Board approved capex for Epoxy Resin & Formulations and Multi-Purpose Plant projects
🔄 What Changed
Revenue grew 15% YoY to ₹709 Crore; PAT rose 25% to ₹99 Crore; EBITDA margin expanded to 25%
🔮 What's Next
Capex projects expected to commission by H2FY28; ongoing CPVC and ECH expansions on schedule
💡 Investor Takeaway
Growth in core chemicals and strategic capex signal long-term diversification and margin expansion potential

Epigral reported Q1FY27 revenue of ₹709 Crore, up 15% YoY, driven by volume growth and improved realization, with EBITDA at ₹179 Crore (25% margin) and PAT at ₹99 Crore (14% margin). The company highlighted 5% sales volume growth and over 80% plant utilization. Strategic capex was approved for a 125,000 TPA Epoxy Resin plant and Multi-Purpose Plant, targeting H2FY28 commissioning, alongside ongoing CPVC and ECH expansions. Capex spend remains on schedule for Q2FY27 completion.

2Financial Results🔴 High Importance ✨ Positive📄 PDF
MetricValue
Revenue₹709 Cr
Net Profit (PAT)₹99
📢 Key Event
Epigral Limited reported Q1FY27 PAT of ₹99 Crore, up 25% YoY from ₹79 Crore.
🔄 What Changed
PAT grew 25% YoY to ₹99 Crore; revenue increased 15% to ₹709 Crore; EBITDA margin stable at 25%; net debt/EBITDA improved to 0.8x.
🔮 What's Next
The company expects to commission both the Epoxy Resin plant and Multi-Purpose Plant in H2FY28.
💡 Investor Takeaway
The results show strong profitability growth and strategic expansion into high-demand specialty chemicals, positioning Epigral for long-term value creation.

Epigral Limited reported Q1FY27 PAT of ₹99 Crore, up 25% YoY from ₹79 Crore, with revenue rising 15% to ₹709 Crore, driven by volume growth and improved realization, while EBITDA margin held at 25% and net debt/EBITDA stood at 0.8x as of June 30, 2026.

📊 Stock Analysis — EPIGRAL✨ Ask AI About This

About Epigral Limited (EPIGRAL)

Chemicals · Chemicals · Listed on NSE

Market Cap: ₹4,388.55 CrP/E: 16.2ROE: 12.2%ROCE: 15.2%Div Yield: 0.49%

View full EPIGRAL stock details →

📡 Get AI alerts when EPIGRAL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track EPIGRAL — Free

💡 Ask AI about this filing

"What is the expected revenue contribution from the new Epoxy Resin plant post-H2FY28?""How will the Multi-Purpose Plant impact EPIGRAL's specialty chemicals revenue mix by FY28?""What is the projected EBITDA margin trajectory for Q2FY27 and beyond?"
Ask AI Free →

📊 More EPIGRAL filings

See all EPIGRAL filings →

🔥 Also filed on 27 July 2026

FAIRCHEMORFairchem Organics LimitedFinancial ResultsMPHASISMphasiS LimitedInsider TradingNTPCNTPC LimitedCorporate ActionCCLCCL Products (India) LimitedCorporate ActionITIITI LimitedAnnouncementSHRIRAMFINShriram Finance LimitedFinancial Results
View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when EPIGRAL files new disclosures

Track EPIGRAL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track EPIGRAL — Free

Free account · 2 AI queries/day